摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Methyl-pyrido<3,4-d>pyrimidin | 51752-73-9

中文名称
——
中文别名
——
英文名称
4-Methyl-pyrido<3,4-d>pyrimidin
英文别名
4-methyl-pyrido[3,4-d]pyrimidine;4-Methylpyrido[3,4-d]pyrimidine
4-Methyl-pyrido<3,4-d>pyrimidin化学式
CAS
51752-73-9
化学式
C8H7N3
mdl
——
分子量
145.164
InChiKey
BUNZGFIINLFNNQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    38.7
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • WNT SIGNALING INHIBITOR
    申请人:KYOWA HAKKO KIRIN CO., LTD.
    公开号:US20160168125A1
    公开(公告)日:2016-06-16
    A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n 1A represents 0 or 1; n 2A and n 3A may be the same or different, and each represents 1 or 2; R OA represents optionally substituted aryl or the like; R 2A represents a hydrogen atom or the like; R 3A represents an optionally substituted aromatic heterocyclic group or the like; X 1A , X 2A , X 3A and X 4A each represent CH or the like; Y 1A represents CH 2 or the like; Y 2A represents N or the like; and L A represents CH 2 or the like).
    提供一种Wnt信号抑制剂,其包括以下式(IA)所表示的融合环杂环化合物作为活性成分或其药学上可接受的盐等:(其中,n1A表示0或1;n2A和n3A可以相同也可以不同,每个表示1或2;ROA表示可选择地取代的芳基或类似物;R2A表示氢原子或类似物;R3A表示可选择地取代的芳香杂环基或类似物;X1A、X2A、X3A和X4A各自表示CH或类似物;Y1A表示CH2或类似物;Y2A表示N或类似物;LA表示 或类似物)。
  • COMPOUNDS
    申请人:Hummersone Marc Geoffrey
    公开号:US20100130473A1
    公开(公告)日:2010-05-27
    Compounds of formula (I): A-B—C and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of formula (i) where R N is H or Me; or B is a divalent C 5 heterocyclic residue containing one or two ring heteroatoms; A is formula (ii) R A3 and R A5 are independently selected from halo, OR O and R AC , where R O is H or Me, and R AC is H or C 1-4 alkyl; X A is selected from N and CR A4 , where R A4 is selected from H, OR O , CH 2 OH, CO 2 H, NHSO 2 Me and NHCOMe; R A2 and R A6 are independently selected from H, halo and OR O ; or R A3 and R A4 together with the carbon atoms to which they are attached, or RA2 and R A3 together with the carbon atoms to which they are attached, may form a C 5-6 heterocylic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of R A2 to R A6 are not H; C is formula (iii) where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CR C6 ; R C3 is selected from H, halo and an optionally substituted N-containing C 5-7 heterocyclic group; R C5 is a group selected from formula (iv) which group may be selected by one or two C 1-4 alkyl groups or a carboxy group; R C6 is H; or, when X and Y are N, R C5 and R C6 (when Z is CR C6 ) together with the carbon atoms to which they are attached may form a fused C 6 aromatic ring selected from the group consisting of formula (v).
    化合物的化学式(I):A-B-C及其异构体,盐,溶剂合物,化学保护形式和前药,其中:B选自式(i)的群,其中RN为H或Me;或B是含有一个或两个环杂原子的二价C5杂环残基;A为式(ii)RA3和RA5分别独立选择自卤,ORO和RAC,其中RO为H或Me,而RAC为H或C1-4烷基;XA选自N和CRA4,其中RA4选自H,ORO,CH2OH,CO2H,NHSO2Me和NHCOMe;RA2和RA6分别独立选择自H,卤和ORO;或RA3和RA4与它们附着的碳原子一起,或RA2和RA3与它们附着的碳原子一起,可以形成一个含有至少一个氮环原子的C5-6杂环或杂芳烃环;如果XA不是N,则RA2至RA6中的1、2或3个不是H;C为式(iii)其中X选自N和CH,Y选自N和CH,Z选自N和CRC6;RC3选自H,卤和一个可选取代的含N的C5-7杂环基团;RC5是从式(iv)中选择的一个或两个C1-4烷基或羧基;RC6为H;或当X和Y为N时,RC5和RC6(当Z为CRC6时)与它们附着的碳原子一起可以形成所选自式(v)的群中的融合C6芳香环。
  • PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS
    申请人:Zhang Junhu
    公开号:US20100222342A1
    公开(公告)日:2010-09-02
    Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    提供了式I的吡咯吡唑化合物,包括这些化合物的组合物和使用它们的方法。式I的优选化合物具有蛋白激酶抑制剂的活性,包括作为PAK4的抑制剂
  • PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS
    申请人:ZHANG Junhu
    公开号:US20120264751A1
    公开(公告)日:2012-10-18
    Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    提供了公式I的吡咯吡唑化合物,包括这些化合物的组合物和使用它们的方法。公式I的优选化合物具有作为蛋白激酶抑制剂的活性,包括作为PAK4抑制剂
  • SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS
    申请人:Carson Kenneth G.
    公开号:US20130123270A1
    公开(公告)日:2013-05-16
    The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
    本发明涉及化合物,作为趋化因子受体拮抗剂有用。提供了一般式I的化合物:或其药学上可接受的盐。该发明还提供了包括所述化合物的药学上可接受的组合物,并使用该化合物和组合物来抑制趋化因子受体以及治疗各种疾病,病况或障碍,包括急性或慢性炎症性疾病,癌症或骨溶解性骨疾病的方法。
查看更多

同类化合物

阿昔替酯 螺喹唑啉 苯并[g][1,2,3]三唑并[4',5':5,6]吡啶并[2,1-b]喹唑啉-13(2H)-酮 脱氢利培酮 盐酸曲林菌素 甲硫利马唑 甲基8-乙基-2-甲氧基-5-氧代-5,8-二氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基8-乙基-2-(甲硫基)-5-氧代-5,6,7,8-四氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基2-乙氧基-8-乙基-5-氧代-吡啶并[6,5-d]嘧啶-6-羧酸酯 溴他替尼 泮托拉唑杂质DF 氨甲酸,[(2R,3E)-2-羟基-3-戊烯基]-,1,1-二甲基乙基酯(9CI) 柱孢藻毒素 曲美替尼 曲美替尼 曲喹辛 异噻唑并[5,4-d]嘧啶,3-亚硝基-(9CI) 帕潘立酮棕榈酸酯 帕潘立酮杂质7 帕潘立酮杂质16 帕潘立酮杂质 帕潘立酮杂质 帕潘立酮去氟杂质 帕潘立酮Z-异构体 帕潘立酮 帕泊昔布杂质117 帕布昔利布杂质46 帕博西尼杂质S 帕利哌酮杂质05 帕利哌酮杂质03 帕利哌酮杂质02 帕利哌酮十四酸酯 帕利哌酮N-氧化物 布喹特林 巴马斯汀 奥卡哌酮 多夸司特 嘧啶并[4,5-d]嘧啶-2,4,5(1H,3H,6H)-三酮,7-乙氧基-1,3-二甲基-6-(苯基甲基)- 吡曲克辛 吡嘧司特钾 吡嘧司特 吡啶并[4,3-d]嘧啶-4(1H)-酮,4,5,6,7-四氢-6-甲基-2-苯基- 吡啶并[4,3-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,4-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,2-d]嘧啶-4(3H)-酮,3-甲基-2-(甲基氨基)- 吡啶并[3,2-d]嘧啶-4(3H)-酮 吡啶并[3,2-d]嘧啶-4(1H)-酮,2,3-二氢-3-(2-羟基苯基)-2-硫代- 吡啶并[3,2-d]嘧啶-2,4(1H,3H)-二酮 吡啶并[2,3-d]嘧啶-7(8h)-酮,2,6-二溴-8-环戊基-5-甲基- 吡啶并[2,3-d]嘧啶-7(8H)-酮